Xadago features the active substance safinamide, a monoamine oxidase-B (MAO-B) inhibitor. It blocks the enzyme monoamine oxidase type B which breaks down dopamine, helping to restore dopamine levels in the brain and enhancing the patient's symptoms.

In long-term double-blind controlled studies, Xadago demonstrated significant effects on motor fluctuations without increasing the risk of developing dyskinesia.

The full article appears in PBR Staff Writer published 16th Novemeber 2015.